April 22, 2014
Elanco acquires Novartis Animal Health
Elanco announces an agreement to acquire Novartis Animal Health, creating a global leader in animal health innovation and customer value. The $5.4 billion deal creates world’s second-largest animal health company.
February 24, 2014
Elanco acquires Lohmann SE
Elanco announces an agreement to acquire Lohmann Animal Health, a privately-held company headquartered in Cuxhaven, Germany. The acquisition will establish Elanco as a global poultry leader, extending our presence into layers and expanding our growing vaccine presence.
February 13, 2014
'Enough is Enough' When It Comes to the Food Security Debate
Innovation, Choice and Trade - the Three Pillars for Ensuring a Food Secure World before 2050
The report, written by Elanco President Jeff Simmons, advocates for farmer access to innovative tools in order to feed a growing global population and save natural resources.
Elanco conducted the second edition (2013) of the International Consumer Attitudes Study to determine the key issues for consumers when buying food. Based on two key criteria – 1) unaided questions and 2) consumer spending data, the research includes 34 studies from 26 countries accounting for more than 100,000 consumers.
For more information, visit www.SensibleTable.com. Join @JeffSimmons2050 and @Elanco for more discussion on Twitter with #FeedThe9. The website calls for advocates to join The Enough Movement and provides resources for campaigners to help make their voices heard in the fight for a food secure tomorrow.
April 10, 2013
Elanco Expands Commitment to China Through Investment in Local Industry Leader China Animal Healthcare
- China investment reinforces Elanco's commitment to China's efforts to ensure food safety and enhance food security and rural income.
- Elanco is a global leader in providing innovative solutions to enhance safe, affordable, abundant food production.
- Minority equity stake in China Animal Healthcare is valued at approximately $100 million USD.
February 16, 2012
Hygromix® returns to help poultry producers fight intestinal worms
Hygromix, an in-feed medication for control of parasite infections in chickens, will once again be available in the United States starting mid-April. Hygromix is the only FDA-approved poultry product that controls all three nematodes; capillary worms (Capillaria obsignata), cecal worms (Heterakis gallinae) and large roundworms (Ascaris galli), and is recommended for pullets and breeders.
- For use as an aid in the control of parasite infections in chicken flocks associated with Ascaris galli, Heterakis gallinae and Capillaria obsignata.
- Mix 1.0–1.5 lbs. Hygromix 8 per ton of Type C medicated feed for 8–12 g of hygromycin B per ton.
- Feeds containing Hygromix must be withdrawn 3 days prior to slaughter.
The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.
April 29, 2011
Elector® PSP label now includes control of northern fowl mites in poultry
Poultry producers have a new tool to help rid birds of a costly health threat. Elector® PSP has received regulatory approval for the control of northern fowl mites (Ornithonyssus sylviarum), the most common external poultry parasite in the United States.
December 17, 2010
Elanco launches milk test strip in United States
Elanco announces the addition of Keto-Test® to its current portfolio of productivity products for dairy producers. Keto-Test is a color-changing test strip that indicates the presence of ketones in the milk of dairy cows. Though commercially available in other countries, this is the first U.S. introduction of the product.
August 24, 2012
Elanco Announces Comfortis® (spinosad) for Cats and Small Dogs
Comfortis® (spinosad), the month-long flavored tablet that has been protecting dogs from fleas since 2007 has now been approved for use in cats and smaller dogs. As a result of the recent FDA approval, Comfortis can now be used in cats and kittens greater than 2 lbs and 14 weeks and older. In addition, our new 90 mg tablet will allow veterinarians to prescribe Comfortis for smaller dogs 3.3-4.9 lbs and 14 weeks and older.
Important safety information
For cats: The most common adverse reaction recorded in clinical trials was vomiting. Other adverse reactions were: lethargy, decreased appetite, weight loss, and diarrhea. Use with caution with concomitant extra-label use of ivermectin.
The safe use of Comfortis in breeding, pregnant, or lactating cats has not been evaluated.
For dogs: The most common adverse reaction reported is vomiting. Other adverse reactions reported in decreasing order of frequency are: depression/lethargy, decreased appetite, incoordination, diarrhea, itching, trembling, excessive salivation and seizures.
Following concomitant extra-label use of ivermectin with Comfortis, some dogs have experienced the following clinical signs: trembling/twitching, salivation/ drooling, seizures, incoordination, excessive dilation of pupils, blindness and disorientation. Post-approval experience continues to support the safety of Comfortis when used concurrently with heartworm preventatives according to label directions.
Use with caution in breeding females and dogs with pre-existing epilepsy. The safe use of Comfortis in breeding males has not been evaluated.
View full product label for complete safety information.